Biotechnology for a quality of life in a sustainable society

1
Biotechnology for a quality of life in a
sustainable society
2
Why do we organise Europ_at_BioVision? 

• Unique place for science, industry and society to
  meet
• Active speaking and listening
• A melting pot of the biotechnology community
• Feel the pulse be emotionally aware

3
Did we succeed?
4
White biotech- Progress, Challenges and
implications for Decision Makers
Green Factory- Beyond Food, a New Deal for
Farmers?
5
White biotech conclusions (1)

• Research
• New technologies such as metagenomics and
  activity-based enzyme discovery will boost the
  discovery of novel enzymes and applications
• New bio-based building blocks will boost chemical
  innovations
• But,
• We have to invest in and support RD and
  innovation
• We have to involve the major players of the
  entire value chain

6
White biotech conclusions (2)

• Policy
• Feedstock price is important and should be
  reduced, especially for large-scale products
• Therefore,
• Research should focus on the conversion of waste
  biomass
• Subsidy distortion should gradually be removed

7
White biotech conclusions (3)

• Communication
• Clean, clever and competitive
• Good awareness and knowledge is key for the
• development and acceptance of white
  biotechnology
• Therefore,
• Scientists and industry should better communicate
  the benefits for the environment AND consumers
  with CONCRETE examples

8
Aging population- Focus on Cancer- Role of public
and private partnerships
9
Healthcare biotech conclusions

• By 2030, there will be
• 27 M new cancer cases per year,
• 17 M deaths from cancer and
• 75M people living with cancer!
• Patient involvement is key and building
  public-private partnership to find solutions to
  bring new drugs to patients and increase RD to
  meet unmet medical needs.
• Finally, according to a EU commission survey,
  Europe is a second class continent in cancer
  research. Europe spends 4 times less in of GDP
  and 7 times less per capita than the USA!

10
Lifestyle and Impact on Disease- Diabetes a Case
Study
11
New developments between nutrition, genomics
health promise, hype or reality?
International Genetic Alliance Invitation to a
reception today at 18.30 at the Lumière Bar
Emerging area - watch this space!
12
Healthcare biotech conclusions

• Genes, lifestyle, nutrition and health are
  linked.
• Both a lack of exercise and a bad diet are known
  risk factors for obesity, Cardio-Vascular disease
  and diabetes
• Solutions might come
• from Nutrigenomics to prevent disease
• a combination of micronutrients to reduce the
  risk of diabetes, and
• the use of molecular diagnosis in early
  detection.

13
Plants of Today- Plants for Tomorrow
14
Plants of today, plants for tomorrow

• Plant genomics and biotechnology is already
  providing new solutions to old problems, and many
  new opportunities
• ? The EuropaBio led European  Plants for the
  Future  Technology Platform is seen as an
  important initiative
• Although there remain considerable concerns about
  growing GM crops in Europe, there are some
  regions that are enthusiastic
• Farmers in Spain are enthusiastic about the
  benefits they obtain through growing insect
  resistant maize - GM maize growers have had no
  problems with their neighbouring non-GM growing
  neighbours
• As the European institutions set co-existence
  rules in place, they should be science based and
  enabling - NOT prohibitory

15
When and where is the next IPO window?
16
Stock markets

• Overcome fragmentation
• Regulated / unregulated stock market and
  harmonisation of securities rules
• Shortage of money
• CriticaI I identifies funding problem
• Exchanges no consensus

17
Trends in Leveraging IP to Create Value
18
Intellectual property

• Sharing knowledge is important social,
  intellectual and financial capital
• Equity gap pre seed incubation project
• Important to develop Strong IP to grow companies
  attractive to venture capitalists

19
Finance for EU Biotech Research
20
Framework programme is here

• Doubling the budget to 73 Billion
• Improving the access for industry
• Matching with EIB for financing the
  infrastructure
• FP7 for 7 years
• DG research Biotechnology commitmentBut,
• We need endorsement of the Parliament and Member
  States of the Commissions enthusiasm!!!

21
EuroBioCluster Networking Europes Biotechnology
Critical Mass and Hubs of Excellence, the two
Triggering Factors
Clusters find each other at the European
level. Get Organised for the common issues.
22
European Space Agency Space for Research
Innovation
Offers of collaborations Private public
collaboration
23
Welcome Impact assessments Relaunch G10 to
include more than pharma but also biotech Get
European enthusiasm for innovation will increase
coherence of policies Predictable and stable
regulatory environment
24
EuropaBio appeal to industry

• We want to learn more from you
• We want to represent you better
• We want to become an integral part of building a
  better biotech community
• Membership is open to all companies also SMEs.
• www.europabio.org